Nicholas Cam

Poseida Therapeutics (United States) — United States

Medicine · Health Sciences

6h-index729citations14works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(6), Lung Cancer Treatments and Mutations(3), T-cell and B-cell Immunology(2), HER2/EGFR in Cancer Research(2), CRISPR and Genetic Engineering(2)

Publications14 total

Sustained FVIII Expression with a Tolerable, Titratable, Fully Non-Viral Gene Therapy for Hemophilia a
Blood·2024Open Access
Supplementary Methods, Figure Legends, Table Legends, Figures S1 - S4, Tables S1 - S5 from Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
2023Open Access
Data from Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
2023Open Access
Data from Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
2023Open Access
Supplementary Methods, Figure Legends, Table Legends, Figures S1 - S4, Tables S1 - S5 from Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
2023Open Access
The Application of ‘Drug-Reversible’ CAR-T Cells Directed Against Recipient Hematopoietic Cells As a Selective Conditioning Strategy for Stem Cell Transplantation
Blood·2017
Abstract 2136: Entrectinib is effective against the gatekeeper and other emerging resistance mutations in NTRK-, ROS1- and ALK- rearranged cancers
Cancer Research·2016· 6 cited
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
Annals of Oncology·2016· 300 citedOpen Access
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model
Cancer Letters·2016· 86 cited
Abstract A173: Potent anti-tumor activity of entrectinib in patient-derived models harboring oncogenic gene rearrangements of NTRKs
Molecular Cancer Therapeutics·2015· 2 cited
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Cancer Discovery·2015· 302 citedOpen Access
Abstract 127: Overexpression of neurotrophic tyrosine receptor kinases (NTRKs) as a potential therapeutic target for cancer
Cancer Research·2015
Regulation of Immune Responsiveness In Vivo by Disrupting an Early T-Cell Signaling Event Using a Cell-Permeable Peptide
PLoS ONE·2013· 8 citedOpen Access
<i>In Vivo</i> Significance of ITK-SLP-76 Interaction in Cytokine Production
Molecular and Cellular Biology·2010· 25 citedOpen Access

Frequent Co-authors

Wei Ge(10), Roopal Patel(8), Mariangela Russo(6), Sandra Misale(6), Alberto Bardelli(6), Robert A. Wild(6), Giulia Siravegna(5), Giovanni Crisafulli(5), Luca Lazzari(5), Giorgio Corti(5), Giuseppe Rospo(5), Luca Novara(5), Benedetta Mussolin(5), Alice Bartolini(5), Shunqi Yan(5), Robert Shoemaker(5), Federica Di Nicolantonio(5), Salvatore Siena(5), Gang Li(4), Zachary Hornby(4)